Are Manufacturers Willing To Do Outcomes-Based Pricing? Payers Are Skeptical
This article was originally published in The Pink Sheet Daily
FDA/CMS Summit speakers say they've yet to see any real interest from manufacturers in putting money at risk if their products don't meet outcome measures.
You may also be interested in...
CMS requests information from hepatitis C manufacturers on how value-based purchasing arrangements might work in Medicaid. Agency also urges state Medicaid directors to relax overly strict coverage requirements for the drugs.
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.